JNJ
Johnson & Johnson · Healthcare · Drug Manufacturers - General
ZACKSHoldTECHSell
R500#421 today
$256.03
-1.02% today · -5.60% 1W
Oct 2 close or latest
PreviewWhy it's moving
Underperforming without a clear catalyst yet
- JNJ −1.02% on the last session vs SPY +0.74%: −1.8 pts of stock-specific move.
- Market backdrop (Fri): Average Hourly Earnings m/m 0.1% vs 0.3% expected (cooler); Non-Farm Employment Change 29K vs 89K expected (weaker); S&P futures +0.41%, 10-year yield -5bp in the 30 minutes after.
Assembled from Wallsti's own signals. The news-reading agent will explain the move with timestamped sources, and say so when there is no clear catalyst.
Next report
Oct 13
Before the open · in 10 days
EPS estimate
$2.48
$2.31 to $2.66 · 8 analysts
Revenue estimate
$25.3B
$25.0B to $25.7B
Track record
7/8 beats
last 8 reports · moved ±1.7% on average
Reports
| Reported | Quarter | EPS est. | EPS | Surprise | Revenue | Reaction | Gap | 5 days |
|---|---|---|---|---|---|---|---|---|
| Jul 15, 2026 BMO | 2Q2026 | $2.85 | $2.90 | +1.6% beat | $25.3B | -2.7% -3.1 vs SPY | -1.5% | -1.3% |
| Apr 14, 2026 BMO | 1Q2026 | $2.68 | $2.70 | +0.8% beat | $24.1B | +0.9% -0.3 vs SPY | -1.2% | -3.1% |
| Jan 21, 2026 BMO | 4Q2025 | $2.46 | $2.46 | -0.1% in line | $24.6B | -0.1% -1.2 vs SPY | -3.3% | +2.9% |
| Oct 14, 2025 BMO | 3Q2025 | $2.76 | $2.80 | +1.5% beat | $24.0B | 0.0% +0.1 vs SPY | +1.1% | +1.5% |
| Jul 16, 2025 BMO | $2.68 | $2.77 | +3.4% beat | — | +6.2% +5.9 vs SPY | +3.3% | +8.2% | |
| Apr 15, 2025 BMO | $2.58 | $2.77 | +7.4% beat | — | -0.5% -0.2 vs SPY | +0.9% | +2.2% | |
| Jan 22, 2025 BMO | $2.01 | $2.04 | +1.5% beat | — | -1.9% -2.5 vs SPY | -2.8% | +1.5% | |
| Oct 15, 2024 BMO | $2.21 | $2.42 | +9.5% beat | — | +1.6% +2.3 vs SPY | -1.0% | +0.8% | |
| Jul 17, 2024 BMO | $2.70 | $2.82 | +4.4% beat | — | +3.7% +5.1 vs SPY | +0.4% | +0.9% | |
| Apr 16, 2024 BMO | $2.65 | $2.71 | +2.3% beat | — | -2.1% -1.9 vs SPY | -1.8% | +1.0% | |
| Jan 23, 2024 BMO | $2.28 | $2.29 | +0.4% beat | — | -1.6% -1.9 vs SPY | -1.7% | -1.9% | |
| Oct 17, 2023 BMO | $2.52 | $2.66 | +5.6% beat | — | -0.9% -0.9 vs SPY | -1.0% | -3.9% | |
| Jul 20, 2023 BMO | $2.62 | $2.80 | +6.9% beat | — | +6.1% +6.7 vs SPY | +2.0% | +8.8% | |
| Apr 18, 2023 BMO | $2.50 | $2.68 | +7.2% beat | — | -2.8% -2.9 vs SPY | -0.9% | -1.2% | |
| Jan 24, 2023 BMO | $2.24 | $2.35 | +4.9% beat | — | 0.0% +0.1 vs SPY | +0.4% | -3.8% | |
| Oct 18, 2022 BMO | $2.49 | $2.55 | +2.4% beat | — | -0.3% -1.5 vs SPY | -0.9% | +2.6% | |
| Jul 19, 2022 BMO | $2.55 | $2.59 | +1.6% beat | — | -1.5% -4.2 vs SPY | +1.2% | -1.0% | |
| Apr 19, 2022 BMO | $2.57 | $2.67 | +3.9% beat | — | +3.0% +1.4 vs SPY | +1.7% | +4.7% | |
| Jan 25, 2022 BMO | $2.12 | $2.13 | +0.5% beat | — | +2.9% +4.1 vs SPY | -0.4% | +5.7% | |
| Oct 19, 2021 BMO | $2.35 | $2.60 | +10.6% beat | — | +2.3% +1.6 vs SPY | +0.5% | +2.5% | |
| Jul 21, 2021 BMO | $2.28 | $2.48 | +8.8% beat | — | — | — | — | |
| Apr 20, 2021 BMO | $2.35 | $2.59 | +10.2% beat | — | — | — | — | |
| Jan 26, 2021 BMO | $1.83 | $1.86 | +1.6% beat | — | — | — | — | |
| Oct 13, 2020 BMO | $1.98 | $2.20 | +11.1% beat | — | — | — | — |
BMO = before the open, AMC = after the close. Reaction: the first session that could trade on the report (the same day for BMO, the next session for AMC) against the close before it; "vs SPY" subtracts the S&P 500 over the same session. Revenue surprise needs the estimate from before the report, so it starts with the reports Wallsti saw coming.
Analyst estimates
| Period | EPS | Range | vs year ago | 90-day trend | Revisions 30d | Revenue | vs year ago |
|---|---|---|---|---|---|---|---|
| Current quarter · Sep 30, 2026 | $2.48 (8) | $2.31 – $2.66 | -11% | -17.9% | — | $25.3B | +6% |
| Next quarter · Dec 31, 2026 | $2.96 (7) | $2.74 – $3.13 | +20% | -1.1% | — | $26.6B | +8% |
| Current year · Dec 31, 2026 | $11.08 (8) | $11.01 – $11.22 | +3% | -4.3% | — | $101.3B | +8% |
| Next year · Dec 31, 2027 | $12.00 (7) | $11.30 – $13.47 | +8% | -5.7% | — | $108.6B | +7% |
Consensus as of Oct 3, 2026. Source: Yahoo Finance analyst estimates; schedule and timing also from Nasdaq's earnings calendar.